| Identification | Back Directory | [Name]
DPO-1 | [CAS]
43077-30-1 | [Synonyms]
DPO-1
DOP-1 (Diphenyl phosphine oxide-1)
(+)-Neomenthyl diphenylphosphine oxide
inhibit,DPO1,Inhibitor,DPO 1,Potassium Channel,DPO-1,KcsA
(1S,2S,5R)-5-Methyl-2-(1-methylethyl)cyclohexyl]diphenyl-phosphine oxide
Phosphine oxide, [(1S,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]diphenyl-
[1S-(1α,2α,5β)]-[5-Methyl-2-(1-methylethyl)cyclohexyl]diphenylphosphineoxide | [Molecular Formula]
C22H29OP | [MDL Number]
MFCD09038567 | [MOL File]
43077-30-1.mol | [Molecular Weight]
340.44 |
| Hazard Information | Back Directory | [Uses]
DPO-1 is a potent inhibitor of the voltage-gated potassium channel subtype Kv1.5 and a blocker of ultrarapid delayed rectifier potassium current. DPO-1 prevents atrial arrhythmia[1][2]. | [Definition]
ChEBI: [[(1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene is a monoterpenoid. | [Biological Activity]
Blocker of I Kur ultrarapid delayed rectifier potassium current and K V 1.5 channels (IC 50 = 0.31 μ M for rK V 1.5). Displays selectivity for inhibition of I Kur over I to (8-fold), I K1 , I Kr and I Ks (20-fold) in native myocytes and selectivity for rat recombinant K V 1.5 over K V 3.1 (~ 15-fold). Increases action potential duration in atrial but not ventricular myocytes and prevents atrial arrhythmia. | [storage]
Store at +4°C | [References]
[1] Lagrutta A, et al. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. DOI:10.1124/jpet.106.101162
[2] Stump GL, et al. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther. 2005 Dec;315(3):1362-7. DOI:10.1124/jpet.105.092197 |
|
| Company Name: |
Shaanxi Dideu Medichem Co. Ltd
|
| Telephone: |
+86-29-81139210 17389186172 |
| Website: |
https://www.chemicalbook.com/manufacturer/shaanxi-dideu-medichem-219/ |
|